Belimumab in systemic lupus erythematosus
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, au...
Main Author: | Ankita Srivastava |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Indian Journal of Dermatology |
Subjects: | |
Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2016;volume=61;issue=5;spage=550;epage=553;aulast=Srivastava |
Similar Items
-
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022-11-01) -
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
by: Francesca Regola, et al.
Published: (2019-04-01) -
Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01) -
Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report
by: Marco Scarati, et al.
Published: (2017-04-01) -
The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
by: Jing Wang, et al.
Published: (2023-02-01)